AGA GUIDELINES Bundle (free trial)

Luminal and Fistulizing Crohn’s Disease - Moderate-Severe

AGA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512411

Contents of this Issue

Navigation

Page 11 of 13

Treatment 12 Table 1. Drug Therapy for the Management of Moderate to Severe CD Drug Induction Maintenance Biologic- naïve induction Infliximab ✔ ✔ ✔* Adalimumab ✔ ✔ ✔* Certolizumab pegol ✔ ✔ Adalimumab + thiopurine vs adalimumab monotherapy ✔ Infliximab + thiopurine vs infliximab monotherapy ✔ Natalizumab × × Ustekinumab ✔ ✔ ✔* Vedolizumab ✔ ✔ ✔* Oral methotrexate monotherapy × × Subcutaneous or intramuscular methotrexate monotherapy ✔ ✔ iopurine monotherapy × ✔ Corticosteroids ✔ × 5-aminosalicylate/sulfasalazine × × Antiobiotic monotherapy Biologic monotherapy vs thiopurine monotherapy ✔ Biologic agents in combination with antibiotics vs biologic monotherapy * Over certolizumab pegol. ✔ = strong recommendation for; ✔ = conditional recommendation for; × = conditional recommendation against; × = strong recommendation against

Articles in this issue

Archives of this issue

view archives of AGA GUIDELINES Bundle (free trial) - Luminal and Fistulizing Crohn’s Disease - Moderate-Severe